← Return to Video Q&A about Amyloidosis – What Patients Need to Know

Event
Video Q&A about Amyloidosis – What Patients Need to Know Event Date: June 4, 2015 | 12:00pm - 1:00pm ET
Comment receiving replies
@bgardner

NEOD001 treatment is protein specific. How far behind will trials/ development of the drug for TTR-WILD BE?

Jump to this post

Replies to "NEOD001 treatment is protein specific. How far behind will trials/ development of the drug for TTR-WILD..."
Christina Bokusky | @BokuskyChri | Jun 5, 2015

The development of monoclonal antibodies for TTR has been reported, but I am not aware of any clinical trials at this time. Hopefully this might be an option, but will probably be at least a few years down the road.

VIEW AND REPLY